3-MMC Therapy Timing for PMS and PMDD Symptom Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pharmacologically active agents for treating menstrual cycle-induced symptoms, such as PMS and PMDD, are costly and have significant side effects, while alternative psychoactive drugs like MDMA can cause serotonin depletion and depression.

Innovation Solution

Administering 3-methylmethcathinone (3-MMC) at specific times relative to the menstrual cycle to treat menstrual cycle-induced symptoms, including PMS and PMDD, with a therapeutically effective amount and regimen to alleviate both somatic and mood-related symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional pharmacologically active agents (SSRIs, anti-inflammatory agents, hormones, dopamine agonists, diuretics) are used to treat menstrual cycle-induced symptoms, then symptom relief is achieved, but cost increases and significant side effects occur

Engineering Contradiction:

Improvesymptom relief effectivenessVSAvoidside effects and cost

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the pharmacological parameter by using 3-MMC, a psychostimulant with a different mechanism of action compared to conventional SSRIs, anti-inflammatory agents, and hormones. This parameter change provides symptom relief while avoiding the significant side effects and high costs associated with conventional treatments

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a short-acting psychostimulant (3-MMC) that provides temporary relief during the critical perimenstrual period. The treatment is administered only when needed (during symptoms) rather than continuously, reducing overall cost and minimizing cumulative side effects while maintaining effectiveness

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If psychoactive drugs like MDMA are used to treat behavioral and mood-related menstrual symptoms, then mood improvement is achieved, but serotonin depletion and depression occur

Engineering Contradiction:

Improvemood symptom reliefVSAvoidserotonin depletion and depression

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts the beneficial mood-enhancing properties of psychostimulants while eliminating the harmful serotonin depletion effect by selecting 3-MMC, which has a different pharmacological profile than MDMA. This allows mood improvement without the rebound depression and serotonin syndrome associated with MDMA

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts the potential harm of psychostimulant use (serotonin depletion) into benefit by carefully selecting 3-MMC, which provides mood improvement through alternative mechanisms that do not deplete serotonin, thereby avoiding the harmful rebound effects while maintaining the therapeutic benefit

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12485100B2Treatment of menstrual cycle-induced symptoms

Publication Date: 2025.12.02 PERIOD PILL BV

AI summary

The present invention relates to methods of treatment of menstrual cycle induced disorders and symptoms with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects suffering from menstrual cycle induced disorders and symptoms. In particular, methods and kits for therapy of menstrual cycle induced disorders and symptoms with 3-MMC for a variety of disorders and/or conditions, including PMS, PMDD and perimenstrual disorders are provided.